Диуретики в современной терапии артериальной гипертензии: какой препарат выбрать?

1. Collins R., MacMahon S. Blood pressure antihypertensuve drug treatment and the risks of stroke and of coronary heard disease. Brit Med Bull 1994; 50 (2); 272-98.

2. Chobanian A.N., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-71.

3. Сидоренко Б.А., Преображенский Д.В. Краткий справочник по лечению гипертонической болезни. М., 1997.

4. Преображенский Д.В., Сидоренко Б.А. Лечение артериальной гипертензии. М., 1999.

5. Сидоренко Б.А., Преображенский Д.В. Диагностика и лечение артериальной гипертензии. Часть вторая. Диуретики и β-адреноблокаторы. М., 2000.

6. Moser M. Clinical management of hypertension. 5th edition. N.Y., 2001.

7. Kaplan N.M. Clinical hypertension. 7th edition. Baltimore, 1998.

8. Kaplan N.M. Diuretics. Cornerstone of antihypertensive therapy. Am J Cardiol 1996; 77 (2): 3B-5B.

9. Puschett J.B. Clinical pharmacological implications in diuretic selection. Amer J Cardiol 1986; 57 (2): 6A-13A.

10. Materson B.J., Epstein M. Thiazide diuretic and derivates - In. F. Messerli (ed.) Cardiovascular therapy. 2Th edition. Philadelphia, 1996; pp. 412-20.

11. Cardiovascular prescribing guide. PDR 2004. 7th edition. AstraZeneca, 2004.

12. Ames R.P., Kuritsky L. Indapamide. Does it differ from low-dose thiazides? In: F.Messerli (ed.) Cardiovascular drug therapy. 2th edition. Philadelphia 1996; pp. 420-34.

13. Астахова А.В., Лепахин В.К. Лекарственные средства: удлинение интервала QT. Безопасность лекарств. Экспресс-информация, 2002; 1: 2-4.

14. Lu Y., Wang Z., Nattel S. Effects of the diuretic agent indapamide on NA+, transient outward, and delayed rectifier currents in canine atrial myocytes. Circ Res 1993; 72: 225-31.

15. Freis E.D. for the Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Effect of age on treatment results. Am J Med 1991; 90 (suppl.3A): 20S -23S.

16. Materson B.J., Reda D.J., Cushman W.C. et al. Single-lrug therapy for hypertension in men. New Engl J Med 1993; 328: 914-21.

17. Materson B.J., Reda D.J., Cushman W.C. et al. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figure and new data. Am J Hypertens 1995; 8: 189-92.

18. Preston R.A., Materson B.J., Reda D.J. et al. Age race subgroup compared with renin profile as blood pressure response to Antihypertensive therapy. JAMA 1998; 280: 1168-72.

19. Morgan T.O., Anderson A.I.E., MacInnis R.J. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolik hypertension. Am J Hypertens 2001; 14 (3): 241-7.

20. Neaton J.D., Grimm R.H., Prineas R.J. et al. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270: 713-24.

21. Williams B., Poulter N.R., Brown M.J. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Brit Med J 2004; 328: 634-40.

22. Ames R.P. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12B-16B.

23. Gottdiener J.S., Reda D.J., Massie B.M. et al. Effect of single drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. Circulation 1997; 95: 2007-14.

24. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting еnzyme inhibitor or calcium-channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT), JAMA 2002; 288: 2981-97.

25. LaCroix A.Z., Winepahl J., White L.R. et al. Thiazide diuretic agents and the incidence of hip fracture. New Engl J Med 1990; 322: 286-90.

26. Multiple Risk Factor Intervention Trial research group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial Finding related to a prior hypothesis of the trail. JAMA 1990; 263: 1795-801.

27. Savage P., Pressel S.L., Curb J.D. et al. Influence of long-term, low-dose, diuretic based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med 1998; 158: 741-51.

28. Berglund G., Andersson O., Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic: a 1-year controlled trial with bendroflumethiazide. Acta Med. Scand 1986; 220: 419-24.

29. Gurwitz J.H., Bohn R.L., Glynn R.J. et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993; 118: 273-8.

30. Gress T.W., Nieto J., Shahar E. et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. New Fngl J Med 2000; 242 (13): 905-15.

31. Savage P., Pressel S.L., Curb J.D. et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med 1998, 158: 741-51.

32. Moser M. Why are physicians not prestipting diuretics more frequently in the management of hypertension? JAMA 1998; 279: 1813-6.

33. Curb J.D., Pressel S.L., Culter J. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92.

34. Psaty B., Smith N.L., Sisovick D.S. et al. Health outcomes associated with antihypertensive therapies used as first-line agents. An systematic renew and meta- analysis. JAMA 1997; 277: 739-45.

35. Neil B. for Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospective designed overviews of randomized trials. Lanset 2000; 3555 (9246): 1955-64.

36. Hughes D., McGuide A. The direct costs to the NHS of discontinuing and switch prescriptions for hypertension. J Human Hypertension 1998; 12: 533-7.

37. Pearce K.A., Furberg C.D., Psaty B.M., Kirk J. Cost-minimization and number needed to treat in uncomplicated hypertension. Amer J Hypertens 1998; 11: 618-29.